Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MethMax trial in rheumatoid arthritis
NL-OMON60883Phase 4Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: CDAI remission at week 24. Started Nov 2024; status: recruiting.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON60883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60883.